Business Context and Reporting Period
Crown Reserve Acquisition Corp. I (CRAC), a Cayman Islands exempted company and emerging growth company, filed this Form 8-K on March 30, 2026. The filing announces the entry into a Business Combination Agreement with Carvix, Inc., a Delaware corporation. The transaction involves the domestication of CRAC to Delaware, followed by a merger with Carvix, which will survive as a wholly-owned subsidiary. The combined entity intends to list on The Nasdaq Stock Market LLC.
Key Financial Metrics and Transaction Structure
This filing is a current report regarding a material definitive agreement and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. Key financial terms of the transaction include:
- Consideration: Carvix stockholders will receive an aggregate of 50,000,001 shares of the Company's common stock at the Effective Time.
- Earnout Structure: Eligible Carvix equityholders may earn up to 50,000,100 additional shares over a four-year period (fiscal years beginning Jan 1, 2027) based on EBITDA and revenue targets.
- Earnout Targets:
- EBITDA: $10.38M (Year 1), $14.95M (Year 2), $21.84M (Year 3), $21.84M (Year 4).
- Revenue: $276.8M (Year 1), $351.71M (Year 2), $436.88M (Year 3), $436.88M (Year 4).
- Sponsor Earnout: The Sponsor may earn up to 3,000,000 shares (1,000,000 per year for Years 1-3) based on milestones, separate from the Company Earnout Shares.
- Warrant Exercise Price: $11.50 per share.
Material Changes and Governance
The filing details significant structural changes pending closing:
- Board Composition: The post-closing board will consist of five members: four nominated by Carvix (including one independent director approved by the Sponsor) and one nominated by the SPAC Sponsor (an independent director approved by Carvix).
- Management: Carvix's existing management team will continue to lead the combined company.
- Stockholder Support: Key Carvix stockholders have entered into a Stockholder Support Agreement to approve the transaction.
- Lock-up: The Sponsor agreed to a lock-up period expiring on the earlier of six months after PIPE financing consummation or eighteen months after Closing.
Guidance, Risks, and Conditions to Closing
The transaction is subject to customary conditions, including stockholder approval, SEC effectiveness of the Form S-4 Registration Statement, Nasdaq listing approval, and the satisfaction of a "Minimum Cash Amount" at closing after redemptions and expenses. The Outside Date for termination is September 30, 2026.
Risks and Contingencies:
- Failure to obtain requisite stockholder approvals from CRAC or Carvix.
- Inability to consummate the transaction due to regulatory orders or antitrust waiting periods.
- Redemption requests by CRAC stockholders reducing cash below the Minimum Cash Amount.
- Failure to realize anticipated benefits or difficulties in integrating the businesses.
- Forward-looking statements regarding future performance are subject to significant risks and uncertainties and are not guarantees.
Investor Verification Checklist
- Verify the final terms of the Business Combination Agreement filed as Exhibit 2.1.
- Review the definitive Proxy Statement/Prospectus (Form S-4) for detailed financial data on Carvix and the combined entity.
- Confirm the status of the "Minimum Cash Amount" condition and potential redemption levels.
- Monitor the approval status of the Form S-4 Registration Statement by the SEC.
- Assess the feasibility of the earnout targets (EBITDA and Revenue) relative to Carvix's historical performance once disclosed.